caa a22 4500 465789641 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF00171848 doi (NATIONALLICENCE)springer-10.1007/BF00171848 Phase II study of tallysomycin S10b in patients with advanced head and neck cancer [Elektronische Daten] [Claude Nicaise, W. Hong, W. Dimery, J. Usakewicz, M. Rozencweig, I. Krakoff] Summary: Twenty patients with advanced head and neck tumors were entered in a phase II trial of tallysomycin S10b given intravenously at weekly doses of 2.5 mg/m2. All patients had received prior chemotherapy ± radiotherapy. Sixteen patients were evaluable for response. Two had stable disease for 15 and 22 weeks respectively. None exhibited tumor shrinkage. Non-hematologic toxicities primarily consisted of gastrointestinal intolerance. Mild fever was noted in about half of the patients and increase in serum creatinine was observed in four. Other side effects consisted of decrease in pulmonary diffusion capacity and skin changes. In conclusion, tallysomycin S10b has no activity in previously treated head and neck cancer patients and has a toxicity spectrum similar to that of bleomycin. Kluwer Academic Publishers, 1990 tallysomycin S10b nationallicence head and neck cancer nationallicence Nicaise Claude Bristol-Myers Company, Pharmaceutical Research and Development Division, 5 Research Parkway, P.O. Box 5100, 06492-7660, Wallingford, CT, USA aut Hong W. University of Texas, M.D. Anderson Cancer Center,, 1515 Holcombe Blvd., 77030, 06492-7660, Houston,, TX, USA aut Dimery W. University of Texas, M.D. Anderson Cancer Center,, 1515 Holcombe Blvd., 77030, 06492-7660, Houston,, TX, USA aut Usakewicz J. Bristol-Myers Company, Pharmaceutical Research and Development Division, 5 Research Parkway, P.O. Box 5100, 06492-7660, Wallingford, CT, USA aut Rozencweig M. Bristol-Myers Company, Pharmaceutical Research and Development Division, 5 Research Parkway, P.O. Box 5100, 06492-7660, Wallingford, CT, USA aut Krakoff I. University of Texas, M.D. Anderson Cancer Center,, 1515 Holcombe Blvd., 77030, 06492-7660, Houston,, TX, USA aut Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 325-328 0167-6997 8:3<325 1990 8 10637 https://doi.org/10.1007/BF00171848 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171848 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Nicaise Claude Bristol-Myers Company, Pharmaceutical Research and Development Division, 5 Research Parkway, P.O. Box 5100, 06492-7660, Wallingford, CT, USA aut NATIONALLICENCE 700 1- Hong W. University of Texas, M.D. Anderson Cancer Center,, 1515 Holcombe Blvd., 77030, 06492-7660, Houston,, TX, USA aut NATIONALLICENCE 700 1- Dimery W. University of Texas, M.D. Anderson Cancer Center,, 1515 Holcombe Blvd., 77030, 06492-7660, Houston,, TX, USA aut NATIONALLICENCE 700 1- Usakewicz J. Bristol-Myers Company, Pharmaceutical Research and Development Division, 5 Research Parkway, P.O. Box 5100, 06492-7660, Wallingford, CT, USA aut NATIONALLICENCE 700 1- Rozencweig M. Bristol-Myers Company, Pharmaceutical Research and Development Division, 5 Research Parkway, P.O. Box 5100, 06492-7660, Wallingford, CT, USA aut NATIONALLICENCE 700 1- Krakoff I. University of Texas, M.D. Anderson Cancer Center,, 1515 Holcombe Blvd., 77030, 06492-7660, Houston,, TX, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 325-328 0167-6997 8:3<325 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer